Pharming Group N.V.
PHARM.AS · AMS
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | €97 | €93 | €79 | €93 |
| % Growth | 4.4% | 17.9% | -14.7% | – |
| Cost of Goods Sold | €7 | €9 | €8 | €12 |
| Gross Profit | €90 | €84 | €71 | €80 |
| % Margin | 92.7% | 90.4% | 89.5% | 86.8% |
| R&D Expenses | €23 | €24 | €21 | €22 |
| G&A Expenses | €17 | €21 | €22 | €46 |
| SG&A Expenses | €51 | €52 | €57 | -€39 |
| Sales & Mktg Exp. | €34 | €31 | €35 | -€85 |
| Other Operating Expenses | -€0 | -€2 | -€0 | €90 |
| Operating Expenses | €74 | €73 | €78 | €74 |
| Operating Income | €16 | €11 | -€7 | €7 |
| % Margin | 16.3% | 11.6% | -8.9% | 7.2% |
| Other Income/Exp. Net | -€3 | -€4 | -€5 | -€0 |
| Pre-Tax Income | €13 | €7 | -€12 | €7 |
| Tax Expense | €5 | €3 | €3 | €4 |
| Net Income | €8 | €5 | -€15 | €3 |
| % Margin | 7.8% | 5% | -18.6% | 3.1% |
| EPS | 0.011 | 0.007 | -0.022 | 0.005 |
| % Growth | 61.4% | 131.8% | -558.3% | – |
| EPS Diluted | 0.011 | 0.007 | -0.022 | 0.005 |
| Weighted Avg Shares Out | 669 | 669 | 669 | 740 |
| Weighted Avg Shares Out Dil | 669 | 669 | 669 | 740 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €1 | €1 | €2 |
| Interest Expense | €8 | €0 | €5 | €1 |
| Depreciation & Amortization | €3 | €3 | €3 | €8 |
| EBITDA | €23 | €10 | -€4 | €16 |
| % Margin | 24.1% | 10.5% | -5.2% | 16.9% |